ELFBAR 600 e-cigarette Nicotine exceeded: UK supermarkets remove products

Feb.17.2023
ELFBAR 600 e-cigarette Nicotine exceeded: UK supermarkets remove products
ELFBAR 600 e-cigarette's nicotine content exceeded limits and caused major retailers to recall and apologize for the incident.

On February 6th, the UK Daily Mail reported that the ELFBAR 600 electronic-cigarette in watermelon flavor contained excessive levels of nicotine. As a result, three major UK supermarket chains removed the product from their shelves and one ELFBAR wholesaler recalled the product. On February 10th, ELFBAR met with the Medicines and Healthcare products Regulatory Agency (MHRA) and issued a statement apologizing and promising to recall the non-compliant products. The MHRA had previously stated in a response to 2FIRSTS that ELFBAR had promised to recall the related products until they meet regulatory requirements.


On February 15th, 2FIRSTS editors contacted and interviewed 20 electronic cigarette wholesalers in the UK regarding an incident. Only three of them were willing to be interviewed.


All three wholesalers stated that they have not yet received a recall notice for the ELFBAR 600 product.


A wholesale specialist at a high-end London distributor of e-cigarette products has told 2FIRSTS that "overdosing" of e-liquid is a fairly common problem, not limited to ELFBAR products. The nicotine concentration in ELFBAR products remains at 2% and within acceptable limits, so the overdosing is simply a case of consumers getting slightly more liquid for their money. This can actually benefit the wholesale industry, allowing consumers to purchase more product for the same price.


At the same time, he also stated that the company's ELFBAR 600 product inventory is currently sufficient, and all are compliant products.


According to a report from retail industry publication Betterretailing, ELFBAR has issued an apology letter stating that it is working around the clock with all of its supply chain partners to replace all inventory and ensure that no products containing pods with a 3ml capacity are available in the UK. A new batch with a 2ml capacity is expected to arrive in the next 30 days.


2FIRSTS informed the wholesale commissioner of the news and he responded by saying, "Although the 'excessive standard incident' has not had any impact on us at present, this is still good news. We hope that this incident will force the compliance process for all products.


In addition, two wholesale companies, Deep Vaping UK and Vape Distribution, were also interviewed over the phone. Both companies stated that they have not received any requests to recall their products. The person in charge at Vape Distribution said that exceeding the nicotine limit is illegal and they hope that all the products they receive are compliant.


Furthermore, on the official website for ELFBAR in the UK (elfbar.co.uk), the homepage banner features the ELFBAR600 product and the watermelon flavor is still available for purchase. As of press time, five supermarket chains have removed the related product from their shelves. These five supermarket chains control over 50% of the market share in the UK.


Source: elfbar.co.uk


Have ELFBAR dealerships not received recall notices because the products are in compliance and do not require a recall, or has ELFBAR failed to follow through on their recall commitment? 2FIRSTS will continue to monitor and provide updates on the situation.


Related reading: "Compilation of articles about ELFBAR 600 product removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA and NIH Release New Wave 8 Restricted-Use PATH Study Data Files
FDA and NIH Release New Wave 8 Restricted-Use PATH Study Data Files
FDA’s Center for Tobacco Products and NIH’s National Institute on Drug Abuse announced that new Wave 8 restricted-use data files from the PATH Study are now available. The files contain data collected between January 2024 and December 2024, including questionnaire data, location characteristics data, and state identifier data.
Apr.17 by 2FIRSTS.ai
Cross-Party Romanian Lawmakers Propose Ban on E-Cigarettes and Heated Tobacco Use in All Enclosed Public Spaces
Cross-Party Romanian Lawmakers Propose Ban on E-Cigarettes and Heated Tobacco Use in All Enclosed Public Spaces
Lawmakers from Romania’s USR, PSD and PNL have submitted a bill that would ban e-cigarettes, vapes and heated tobacco devices in all enclosed public spaces. The proposal would redefine “smoking” so that inhaling aerosols produced by heating or vaporizing products containing tobacco, nicotine or other substances intended for inhalation would also be considered smoking, except for medical-use products.
Apr.17 by 2FIRSTS.ai
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands reported first-quarter 2026 results on May 7, covering the period ended March 31, 2026. Total consolidated net sales were $124.3 million, up 16.8% year on year. Gross profit was $68.3 million, up 14.6%, while net income fell 19.0% to $11.7 million. Adjusted EBITDA declined 6.5% to $25.9 million.
May.08 by 2FIRSTS.ai
KT&G Overseas Tobacco Revenue Jumps 24.6%, Attracting Global Capital
KT&G Overseas Tobacco Revenue Jumps 24.6%, Attracting Global Capital
South Korean tobacco company KT&G is drawing growing global investor attention after reporting record overseas tobacco sales, with international institutions including Capital Group and BlackRock increasing their stakes.
Business
May.19
NACS Urges USTR to Address Illegal E-Cigarette Exports in China Trade Engagements
NACS Urges USTR to Address Illegal E-Cigarette Exports in China Trade Engagements
NACS submitted a comment letter to USTR in a proceeding examining unfair trade practices worldwide. The letter focuses on illicit nicotine products made in China and shipped to the United States in violation of U.S. law. NACS said the U.S. electronic nicotine delivery systems market has become dominated by illicit products, mainly disposable e-cigarettes manufactured in China and sold without the marketing authorization required by the U.S. Food and Drug Administration.
Apr.16 by 2FIRSTS.ai
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
Ahead of World No Tobacco Day 2026, WHO released its first global report on nicotine pouches, warning that rapid market growth, youth-oriented marketing and weak regulation are converging. 2Firsts views the report as an important warning, but not a complete risk assessment, with harm-reduction questions still unresolved.
Special Report
May.17